The extremely poor prognosis of patients with metastatic osteosarcoma indicates the need for novel therapeutic approaches. Ectodysplasin-A2 (EDA-A2) is a recently isolated member of the tumor necrosis factor superfamily that binds to X-linked ectodermal dysplasia receptor (XEDAR). In this report, we have analyzed the biological activity of EDA-A2 against osteosarcoma-derived cell lines. We report that XEDAR is expressed in cell lines derived from osteosarcoma and adenoviral-mediated expression of EDA-A2 in these cells results in the induction of apoptosis via caspase activation and cell-cycle arrest in the G 0 /G 1 phase. Treatment with EDA-A2 also upregulates the expression of alkaline phosphatase, a marker of osteogenic differentiation, in a caspase-dependent fashion. Collectively, our results suggest that EDA-A2 may be a promising agent for the gene therapy of osteosarcoma.
Introduction
The tumor necrosis factor (TNF) superfamily members play a crucial role in many physiological and pathological responses by activating a variety of intracellular signaling pathways.
1,2 Ectodysplasin A is a recently isolated ligand of the TNF family that plays a key role in ectodermal differentiation. 3, 4 Several alternatively spliced transcripts of EDA have been identified. [4] [5] [6] The two predominant splice variants, EDA-A1 and EDA-A2, differ from each other by a two amino-acid motif and bind to distinct receptors. 7 Thus, EDA-A1 binds to a TNF family receptor designated ectodermal dysplasia receptor (EDAR), while EDA-A2 binds to the related receptor, X-linked ectodermal dysplasia receptor (XEDAR). 7 XEDAR has been shown to lead to activation of the NF-kB, JNK and ERK signaling pathways mainly via TRAF6 and TRAF3. 7, 8 Although XEDAR lacks a death domain, we recently demonstrated that it can nevertheless induce apoptosis when overexpressed in 293T cells by transient transfection. 9 We further showed that EDA-A2
can induce apoptosis in a subclone of 293 cells that had been engineered to stably overexpress XEDAR using retroviral-mediated gene transfer. 9 The apoptosisinducing ability of XEDAR is dependent on the activation of caspase-8 and can be blocked by its genetic and pharmacological inhibitors. 9 However, the biological activities of EDA-A2 on cells that endogenously express XEDAR have not been investigated so far. In this report, we have investigated the expression and signaling activities of XEDAR in osteosarcoma-derived cell lines. We report that EDA-A2 blocks cellular proliferation and induces osteogenic differentiation and apoptosis in osteosarcoma cell lines. Our results suggest that EDA-A2 may represent a promising agent for the gene therapy of osteosarcomas.
Materials and methods

Cell lines and reagents
The human osteosarcoma cell lines SaOS2, U2OS and MG63 were obtained from the American type culture collection (ATCC; Manassas, VA). SaOS2 and U2OS cells were maintained in McCoy 5A medium supplemented with 15% fetal calf serum (FCS). MG63 cells were maintained in minimum essential medium supplemented with 10% FCS at 371C in 5% CO 2 . BC-1 cells were cultured in RPMI medium supplemented with 20% FCS and primary mouse embryonic fibroblast (MEF) cells were maintained in Dulbecco's modified Eagle's medium with 10% FCS. All cell lines were maintained at 371C in 5% CO 2 . Recombinant EDA-A2 was purified as described previously by Chang and Chaudhary, 10 and used at a concentration of 50-200 ng/ml.
Reverse transcription-PCR Total RNA was isolated using RNeasy mini kit following the manufacturer's instructions (Qiagen, Valencia, CA). First-strand cDNAs were prepared from each sample using RNA PCR core kit (ABI) and were used as templates in reverse transcription (RT)-PCR to amplify XEDAR. The primer sequences used were: XEDAR-F, 5
0 -AACAGACATTGCCAGCGTG-3 0 and XEDAR-R, 5 0 -TT GCAGGTCCAGCTCTGTGCATT-3 0 , and G3PDH-
0 . PCR conditions used were: 1 min at 941C followed by 35 cycles of 20 s at 941C, 20 s at 551C, 20 s at 721C and a final extension of 5 min at 721C.
Western blotting
Cells were lysed in a lysis buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1.5 mM MgCl 2 , 2 mM ethylenediaminetetraacetic acid, 2 mM ethylene glycol bis(b-aminoethylether)-N,N,N',N'-tetraacetic acid, 1% Triton X-100, 1 mM Na 3 VO 4 , 1 mM sodium pyrophosphate, 0.1 mM b-glycerophosphate, 10% glycerol supplemented with a protease inhibitor cocktail tablet (Roche, Indianapolis, IN). Western blot analysis was performed essentially as described previously. 11 Antibodies against cleaved caspase-3, -8, -9 and cleaved PARP (poly ADPribose polymerase) were purchased from Cell Signaling (Beverly, MA). An XEDAR antibody was purchased from Pro-science (Poway, CA). All antibodies were used at a dilution of 1:1000.
Adenoviral vectors and infection
Recombinant adenovirus encoding EDA-A2 was generated using Adeno-X expression system according to the manufacturer's instructions (Clontech, Mountain View, CA). For infections, target cells were seeded at 3-5 Â 10 4 cells/well of a 24-well plate in 500 ml of growth medium. The next day, the growth medium was removed and replaced with 250 ml of virus (diluted in complete growth medium with serum to achieve the desired multiplicity of infection (MOI)). Plates were tapped to spread the virus evenly and placed back in the incubator 5 h post-incubation at 371C, 1 ml of fresh medium was added. The effect of viral infection on cell viability and proliferation was analyzed 48-96 h post-infection. Essentially, a similar procedure was used for infection of cells in 96 well and 100 mm plates except the number of cells and the volume of virus was modified proportionally. Determination of apoptosis and caspase activation SaOS2 cells were infected with either Ad-LacZ or Ad-EDA-A2 (MOI ¼ 200) for 72 h, resuspended in binding buffer and then stained with Annexin V-FITC and propidium iodide (PI) following the instructions of the manufacturer (Clontech). The cells were analyzed by flow cytometry. FITC and PI fluorescence were measured in the FL1 and FL2 channels, respectively. For caspase activation assay, the virally infected cells were lysed and equal amounts (2 mg) of protein lysates were used for the measurement of caspase-3 activity using a fluorometric homogenous caspase assay kit (Roche, Indianapolis, IN).
Cell viability and proliferation assays
Cell-cycle analysis with flow cytometry
To measure the effect of EDA-A2 on the cell cycle, SaOS2 cells were treated with 200 ng/ml of recombinant EDA-A2 protein for 72 h, washed and fixed with 70% ethanol at 41C. After incubation overnight, cells were treated with 50 mg/ml RNase for 30 min at 371C and then stained with 40 mg/ml PI. Cells were analyzed on a flow cytometer (FACScan, Becton-Dickinson, San Jose, CA).
Alkaline phosphatase analysis
SaOS2 cells cultured in a 24-well plate were infected with either Ad-LacZ or Ad-EDA-A2 at MOI 50 for 48 h in the presence or absence of 50 mM z-VAD. Then the cells were lysed in 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% NP-40 and analyzed with phosphatase substrate (Sigma, St Louis, MO). Statistical significance of the change in the alkaline phosphatase (ALP) activity in paired samples was determined by Student's t-test using SAS Software version 9.1.2.
Results
XEDAR is expressed in osteosarcoma-derived cell lines
We were interested in studying the effect of EDA-A2 signaling in cells with endogenous expression of XEDAR and used RT-PCR to screen different cell lines for XEDAR mRNA expression. As shown in Figure 1a , we readily detected XEDAR mRNA expression in three osteosarcoma-derived cell lines: SaOS2, U2OS and MG63. In contrast, no expression of XEDAR was seen in BC-1 cells, a primary effusion lymphoma cell line. The expression of XEDAR in the three osteosarcoma cell lines was confirmed at the protein level by immunoblotting with an XEDAR monoclonal antibody (Figure 1b) .
EDA-A2 induces apoptosis in osteosarcoma cells
B Chang et al
EDA-A2 reduces cell viability and induces apoptosis in osteosarcoma cells
To investigate the effect of EDA-A2 on the survival and proliferation of osteosarcoma cells lines, we generated an adenovirus encoding full-length EDA-A2 cDNA (Ad-EDA-A2). An adenovirus vector encoding b-galactosidase (Ad-LacZ) was generated in parallel to serve as a control. SaOS2 cells were infected with the two viruses at increasing multiplicities of infection (MOI) and cell viability was measured approximately 72 h post-infection using an MTS-based assay. As shown in Figure 2a , infection of SaOS2 cells with Ad-EDA-A2 virus resulted in a dose-dependent decrease in cell viability, with cell viability reduced to o20% upon infection with the virus at MOI of X400. In contrast, infection with Ad-LacZ virus had only a marginal effect on cell viability even at the highest tested viral dose (that is, cell viability 475% at MOI ¼ 5000). To examine whether Ad-EDA-A2-induced decrease in cell viability was accompanied by the induction of apoptosis, we used staining with Annexin V/PI followed by flow cytometry. As shown in Figure 2b , a significant increase in both early-(Annexin V þ /PI À ) and latephase (Annexin V þ /PI þ ) apoptotic cells occurred in Ad-EDA-A2-infected SaOS2 cells when compared with Ad-LacZ-infected cells. Induction of apoptosis in Ad-EDA-A2-infected cultures was also confirmed by staining with the nuclear dye Hoechst 33342, which showed cells with condensed and fragmented nuclei (Figure 2c ). In contrast, AD-EDA-A2 failed to induce apoptosis in BC-1 cells, which lack XEDAR expression (Figure 2c ).
EDA-A2-induced apoptosis is associated with the activation of the caspase cascade Death ligands of the TNF family members are known to induce apoptosis via the activation of the caspase cascade.
To study the mechanism of EDA-A2-induced apoptosis in SaOS2 cells, we measured the activation of the caspase cascade by a homogenous caspase assay. As shown in Figure 3a , infection with Ad-EDA-A2 led to a significant increase in caspase activity at 48 and 72 h post-infection as compared to the mock-infected or Ad-LacZ-infected cells, which was effectively blocked by pretreatment of cells with zVAD.fmk, a cell-permeable caspase inhibitor. Infection with Ad-LacZ virus resulted in a marginal increase in caspase activity over the mock-infected cells at 48 h (Figure 3a) and probably reflected non-specific cellular toxicity secondary to viral infection.
Caspase-8 acts as the apical caspase in apoptosis induced by the death receptors of the TNFR family and activates caspase-3 either directly or via tBid-mediated activation of caspase-9. We used immunoblotting to analyze the activation of various caspases during EDA-A2-induced apoptosis of SaOS2 cells. As shown in Figure 3b , we observed cleavage of caspase-8, -9 and -3 into their active fragments within 48 h after infection of SaOS2 cells with the Ad-EDA-A2 virus, which was accompanied by cleavage of PARP, a downstream target of the caspase cascade. In contrast, no caspase-or PARPcleavage was observed in cells infected with the control Ad-LacZ virus (Figure 3b) . Pretreatment with zVAD.fmk effectively blocked activation of caspases and resultant cleavage of PARP in the Ad-EDA-A2-infected cells, thereby demonstrating the specificity of the process (Figure 3b ).
EDA-A2 blocks proliferation of osteosarcoma cell lines
We also examined the effect of recombinant EDA-A2 on the induction of apoptosis in the MG63 osteosarcoma cell line and normal MEF cells. While treatment with recombinant EDA-A2 led to a mild increase in apoptosis in these cells, a significant decrease in cell number was observed which could not be accounted for by the induction of apoptosis (Figure 4) . In contrast, treatment with EDA-A2 had no significant effect on MEF cells. We observed a similar decline in cell number in MG63 and SaOS2 cells that had been infected with the Ad-EDA-A2 virus as compared to those that had been mock infected or infected with the Ad-lacZ virus (data not shown). These experiments were conducted at a lower MOI as compared to those described in Figure 2 (MOI of 50 vs 200) and failed to induce significant apoptosis. To provide an explanation for the decline in cell number, we measured the effect of EDA-A2 on cell proliferation using a BrdU incorporation assay. As shown in Figures  5a and b , this assay demonstrated a significant block in cell proliferation upon infection with the Ad-EDA-A2 virus in both MG63 and SaOS2 cells. Consistent with the above results, a cell-cycle analysis showed accumulation of cells in the G 0 /G 1 phase of the cell cycle upon treatment with EDA-A2 (Figure 5c ). Taken together, these results suggest that EDA-A2 inhibits proliferation of osteosarcoma cells by causing cell-cycle arrest in the G 0 /G 1 phase. 
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EDA-A2 induces osteoblast differentiation through caspase activation
We next investigated whether EDA-A2-induced cell-cycle arrest of osteosarcoma cells is associated with the upregulation of markers of osteogenic differentiation. SaOS2 cells were infected with Ad-EDA-A2 or Ad-LacZ at an MOI of 50, which does not induce significant cell death, and induction of osteoblast differentiation was determined by measurement of ALP. As shown in Figure 6 , treatment of SaOS2 cells with Ad-EDA-A2 for 48 h dramatically increased ALP activity up to threefold over the control. Recent studies implicate caspase activation in osteoblast differentiation. 13 Therefore, we examined the effect of caspase inhibitor zVAD.fmk on EDA-A2-induced ALP activity. Interestingly, pretreatment with pancaspase inhibitor z-VAD.fmk effectively blocked the effect of EDA-A2 on ALP production in the SaOS2 cells (*Po 0.05; Student's t-test, Figure 6 ), suggesting that EDA-A2 induces markers of osteogenic differentiation in SaOS2 cells through caspase activation. Although a slight decrease in ALP activity following z-VAD.fmk treatment was also observed in Ad-LacZ- 
Discussion
The role of EDA-A2/XEDAR in ectodermal differentiation is well documented in the literature.
14 In this report, we present evidence that XEDAR is also expressed in osteosarcoma-derived cell lines. Thus, EDA-A2 and XEDAR may have biological functions beyond their previously documented roles in ectodermal differentiation.
Although XEDAR lacks a death domain, we have previously reported that overexpression of XEDAR in 293T cells leads to induction of caspase-dependent cell death. 9 Furthermore, we have shown that treatment with EDA-A2 leads to induction of cell death in a subclone of 293 cells which had been engineered to overexpress XEDAR by retroviral-mediated gene transfer. 9 In this report, we extend our previous studies and demonstrate that the apoptosis inducing ability of XEDAR and EDA-A2 is not limited to cell lines which overexpress XEDAR and can be observed in cells with endogenous expression of XEDAR as well.
While infection with Ad-EDA-A2 at high MOI (that is, MOI ¼ 200) resulted in apoptosis, infection with a lower MOI (that is, MOI ¼ 50) induced cell-cycle arrest and markers of osteoblastic differentiation. Interestingly, EDA-A2-induced ALP upregulation in SaOS2 cells could be inhibited by treatment of cells with zVAD.fmk, a pancaspase inhibitor, which indicates the involvement of the caspase cascade in this process. Although, caspases were initially believed to be primarily involved in the induction of apoptosis and secretion of proinflammatory cytokines, recent studies have revealed a key role of these proteases in several additional physiological processes such as lymphocytic activation and proliferation, skeletal muscle differentiation and macrophage differentiation. [15] [16] [17] [18] [19] More importantly, and consistent with our results, a recent study demonstrated that bone-morphogenetic protein 4 (BMP-4) induced differentiation of MC3T3-E1 cell line into osteoblasts was associated with activation of caspase-8, -2 and -3. 13 Furthermore, similar to our results, BMP-4 induced cell-cycle arrests and osteoblast differentiation could be blocked by caspase inhibitors. 13 The crucial role of caspase cascade in osteogenic differentiation is also supported by another recent study which reported delayed ossification and decreased bone mineral density in caspase-3-deficient mice due to decreased osteogenic differentiation of bone marrow stromal stem cells. 20 Taken together with these published studies, our results strongly support the hypothesis that EDA-A2 induces osteoblastic differentiation via the activation of the caspase cascade.
Osteosarcoma is one of the most frequent malignant tumors of bone in children and adolescents. 21, 22 Patients with osteosarcoma have extremely poor survival when treated with surgery and/or radiotherapy. 21, 22 Although multiagent chemotherapy has improved the outcome of these patients somewhat, novel treatment approaches are still needed for the management of patients with osteosarcoma, particularly those with metastatic disease. 21, 22 Several mechanisms have been proposed to explain the resistance of osteosarcoma cells to cancer chemotherapy drugs, including mutations in the p53 pathway and defects in the intrinsic apoptotic pathway. 22 Unlike chemotherapy, death receptors belonging to the TNF receptor family can induce apoptosis in a 
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B Chang et al p53-independent fashion. 2, 23 As such, several studies have examined the ability of the death ligands of the TNF family to overcome resistance to chemotherapy in patients with solid tumors. 2, 23 The clinical utility of two such death ligands, TNF-a and FasL, has been limited due to unacceptable systemic toxicity, although isolated limb perfusion of TNF-a has been used for the treatment of extremity soft-tissue sarcomas. 24 Recent studies in this field have focused on TNF-related apoptosis inducing ligand, another death ligand of the TNF family. 25 In the present study, we provide evidence that EDA-A2 can induce cell-cycle arrest, osteoblastic differentiation and apoptosis in osteosarcoma-derived cell lines without significant toxicity on normal MEF cells. Thus, EDA-A2 may be a promising agent for the gene therapy of osteosarcoma and further studies involving this agent, when used alone or in combination with chemotherapy and radiotherapy, deserve consideration.
